Hydroxychloroquine compared with placebo in rheumatoid arthritis. A randomized controlled trial

Area of Science:

• Rheumatology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease.
• Effective early treatment is crucial to prevent joint damage.

Purpose of the Study:

• To evaluate the efficacy of hydroxychloroquine (400 mg daily) in patients with early rheumatoid arthritis.

Main Methods:

• A six-month, double-blind, randomized controlled trial.
• 126 patients with early RA were randomized to receive hydroxychloroquine or placebo.
• Outcomes assessed included joint score, pain, grip strength, and global assessments.

Main Results:

• Hydroxychloroquine showed significant improvements in joint scores, pain, and grip strength versus placebo.
• Greater patient and physician global assessments of improvement were observed with hydroxychloroquine.
• Side effects were mild, with high patient compliance and no discontinuations due to adverse events.

Conclusions:

• Hydroxychloroquine is a moderately effective treatment option for early rheumatoid arthritis.
• The drug demonstrates a favorable benefit-risk profile in this patient population.